NCT00677261

Brief Summary

Many methods of pain relief have been implemented in an attempt to provide safe and effective analgesia for patients following total knee arthroplasty. Numerous studies have demonstrated that nerve blocks can provide superior pain control and reduce side effects. There are two major nerves that provide sensation to the knee: the femoral nerve provides sensation to the front of the knee and sciatic nerve provides sensation to the back of the knee. Putting local anesthetic close to these nerves provides superior pain control. The literature has supported the use of femoral nerve block for analgesia as well as improved functional outcome after total knee arthroplasty. The purpose of this study is to see if the same is true for sciatic nerve block for the back of the knee. We also would like to study an alternative approach to make the back of the knee pain free. This involves injecting local anesthetic directly into this area at the end of your surgery.Patients will be randomized into 3 groups: sciatic block, posterior infiltration of local anesthetic and placebo.This study will help further define the role of sciatic nerve block as well as the alternative technique of local anesthetic infiltration in the perioperative analgesic regimen of total knee arthroplasty surgery, in an effort to develop a standardized perioperative protocol for this patient population. The advent of this protocol should allow reduced risk, improved analgesia, and potentially earlier discharged from hospital with better function.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2008

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 14, 2008

Completed
18 days until next milestone

Study Start

First participant enrolled

June 1, 2008

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
Last Updated

November 21, 2014

Status Verified

July 1, 2011

Enrollment Period

4.3 years

First QC Date

May 12, 2008

Last Update Submit

November 19, 2014

Conditions

Keywords

KneeArthroplastySciaticNerveBlockRegionalAnesthesiaInfiltrationLocal AnestheticAnalgesia

Outcome Measures

Primary Outcomes (1)

  • Visual Analog Scale (VAS) for pain will be used (0=no pain, 100mm = terrible pain) as our primary outcome, for 72 hours post-operatively (at rest and during mobilization).

    On arrival to PACU and every 4 hours thereafter.

Secondary Outcomes (1)

  • The TUG (Timed up and go test) and Range of motion.

    Performed on day 2 and 3.

Study Arms (3)

1

EXPERIMENTAL
Procedure: Sciatic Nerve Block

2

EXPERIMENTAL
Procedure: Posterior capsule infiltration with local anesthetic

3

SHAM COMPARATOR
Procedure: Sham sciatic block and sham posterior infiltration

Interventions

Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.

1

Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.

2

Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.

3

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists physical status I and III
  • Scheduled for total knee arthroplasty

You may not qualify if:

  • Patients not providing informed consent.
  • Refusal of treatment plan.
  • Preexisting medical/neurological/hematologic conditions contraindicated for spinal anesthesia or peripheral nerve blocks.
  • Revision total knee arthroplasty.
  • Known allergy to any of the medications being used.
  • History of drug or alcohol abuse.
  • Patients with chronic pain on slow-release preparations of opioid in excess of 30mg of morphine equivalence per day.
  • Patients with Rheumatoid Arthritis.
  • Patients with psychiatric disorders.
  • Patients unable or unwilling to use Patient Controlled Analgesia.
  • Diabetic patients or those with impaired renal function (Creatinine \>106).
  • Obese patients (i.e. BMI \>45).
  • Postoperatively, patients will be excluded if they have had additional operative procedures requiring a change in the usual rehabilitation protocol of care.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Holland Orthopedic and Arthritic Centre

Toronto, Ontario, M2N-3Y7, Canada

Location

MeSH Terms

Conditions

Bites and StingsAgnosia

Interventions

Anesthetics, Local

Condition Hierarchy (Ancestors)

PoisoningChemically-Induced DisordersWounds and InjuriesPerceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnestheticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic Uses

Study Officials

  • Ben Safa, MD, FRCPC

    Staff Anesthesiologist, Sunnybrook Health Sciences Centre.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD FRCPC Anesthesiologist

Study Record Dates

First Submitted

May 12, 2008

First Posted

May 14, 2008

Study Start

June 1, 2008

Primary Completion

September 1, 2012

Study Completion

November 1, 2012

Last Updated

November 21, 2014

Record last verified: 2011-07

Locations